SOUTH SAN FRANCISCO, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central

Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3 Studies in Acute Treatment of Social Anxiety Disorder SOUTH SAN FRANCISCO, Calif. , Oct.

Preclinical study of intranasal radiolabeled PH94B in laboratory rats further differentiates PH94B’s mechanism of action from benzodiazepines SOUTH SAN FRANCISCO, Calif. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing a new generation

PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder SOUTH SAN FRANCISCO, Calif. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing

SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous

PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan Additional potential NDA-enabling clinical studies expected to initiate in 2021 SOUTH SAN FRANCISCO, Calif., Aug.

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous

Ms. FitzPatrick, an internationally recognized corporate affairs executive, brings extensive healthcare consumer engagement, marketing and public relations expertise to the Company’s Board SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc .

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous